Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

Literature DB >> 11422191

From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

S Y Patel, D S Kumararatne.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2001 PMID： 11422191 PMCID： PMC1906060 DOI： 10.1046/j.1365-2249.2001.01565.x

Source DB: PubMed Journal: Clin Exp Immunol ISSN： 0009-9104 Impact factor: 4.330

× No keyword cloud information.

31 in total

1. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies.

Authors: J Neppert; K Kissel
Journal: Lancet Date: 1992-06-13 Impact factor: 79.321

Review 2. IGIV in neurology--evidence and recommendations.

Authors: V Bril; K Allenby; G Midroni; P W O'Connor; J Vajsar
Journal: Can J Neurol Sci Date: 1999-05 Impact factor: 2.104

3. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

Authors: J Wada; N Shintani; K Kikutani; T Nakae; T Yamauchi; K Takechi
Journal: Clin Exp Immunol Date: 2001-05 Impact factor: 4.330

4. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis.

Authors: J Pizzuto; R Ambriz
Journal: Blood Date: 1984-12 Impact factor: 22.113

5. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors: P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal: Lancet Date: 1981-06-06 Impact factor: 79.321

6. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

Authors: M Debré; M C Bonnet; W H Fridman; E Carosella; N Philippe; P Reinert; E Vilmer; C Kaplan; J L Teillaud; C Griscelli
Journal: Lancet Date: 1993-10-16 Impact factor: 79.321

Review 7. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.

Authors: B Pirofsky; D M Kinzey
Journal: Drugs Date: 1992-01 Impact factor: 9.546

8. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect.

Authors: J B Bussel; J N Graziano; R P Kimberly; S Pahwa; L M Aledort
Journal: Blood Date: 1991-05-01 Impact factor: 22.113

From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

1. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies.

Review 2. IGIV in neurology--evidence and recommendations.

3. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

4. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis.

5. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

6. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

Review 7. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.

8. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect.

9. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].

10. High-dose intravenous gammaglobulin for Kawasaki disease.

Review 1. Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Review 2. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

3. Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report.